Skip to ContentSkip to Navigation
About us Faculty of Science and Engineering Our Research GRIP News and activities Agenda

PhD defence Y. Tian

When:Fr 23-10-2020 09:00 - 10:00
Where:Academy Building

Blends of trehalose and pullutan to stabilize biopharmaceuticals in alternative dosage forms: orodispersible films and dissolving microneedles

Biopharmaceuticals, e.g. proteins and vaccines, have become the fastest growing class of medicines in today’s pharmaceutical markets. However, a broader application of biopharmaceuticals is hampered by two major challenges, i.e. instability of these products and limitations with respect to the route of administration.

In her PhD-study, Yu Tian investigated possible solutions for these two challenges. Biopharmaceuticals can be stabilized by drying them in the presence of sugars. Tian: "We found that using a combination of a low molecular weight sugar (trehalose) and a high molecular weight polysaccharide (pullulan) provided excellent stability to beta-galactosidase (a model protein) during drying and storage in particular when exposed to high humidities. These results were ascribed to the ability of trehalose to form a compact coating around the protein and the excellent physical properties of pullulan. Most biopharmaceuticals are administrated via injection, which harbors several drawbacks. Therefore, in this PhD-study two alternative dosage forms have been explored. Amongst other biopharmaceuticals, whole inactivated influenza virus vaccine (WIV), was incorporated in either orodispersible films (ODFs) for oral administration or dissolving microneedles for intradermal delivery. Trehalose and pullulan were employed as stabilizing excipients. WIV showed very good stability during preparation of both of these alternative dosage forms and during subsequent storage. Furthermore, the ODFs showed the required mechanical properties and fast dissolution behavior. Also, the microneedles showed the required mechanical properties as they could efficiently penetrate human skin ex vivo. Future in vivo experiments have to show the potential of these two dosage forms."

Promotores: Prof.dr. H.W. Frijlink

printView this page in: Nederlands